Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2167-2176

  Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Cortes, Jorge E ^a   Smith, Terry L ^a   Rios, Mary Beth ^a   Shan, Jianqin ^a   Yang, Ying ^a   Giles, Francis J ^a   Thomas, Deborah A ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Jeha, Sima ^a   Wierda, William ^a   Issa, Jean Pierre J ^a   Kornblau, Steven M ^a   Keating, Michael ^a   Resta, Debra ^a   Capdeville, Renaud ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE PAIN; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; EDEMA; ENZYME INHIBITION; ENZYME SPECIFICITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE CRAMP; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; RASH; SPLENOMEGALY; SURVIVAL RATE; SURVIVAL TIME; VOMITING; ADOLESCENT; BONE MARROW; CHROMOSOME ANALYSIS; DRUG ANTAGONISM; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYELOID LEUKEMIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; CYTOGENETIC ANALYSIS; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMAN; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGE; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASE; PYRIMIDINES; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; TREATMENT OUTCOME; HUMANS; MIDDLE AGED; PROTEIN-TYROSINE KINASES;

EID: 0035992318     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chronic myelogenous leukemia: A concise update
2. Treatment of chronic myelogenous leukemia: Current status and investigational options
3. Chronic myelogenous leukemia: Biology and therapy
4. Characteristics of accelerated disease in chronic myelogenous leukemia
5. Characteristics of the terminal phase of chronic granulocytic leukemia
6. Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse
7. Blastic phase of chronic myeloid leukemia (b1VML): A proposal for standardization of diagnostic and response criteria
8. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
9. Bone marrow transplantation for chronic myeloid leukemia: Long term results
10. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia (Baltimore)
11. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia
12. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
13. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine and granulocyte macrophage colony stimulating factor
14. Treatment of advanced stages of Philadelphia chromosome positive chronic myelogenous leukemia with interferon-α and low dose cytarabine
15. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
16. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
17. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
18. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
19. r 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
20. Efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia
21. Activity of an abl specific tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis and other Philadelphia chromosome positive acute leukemias
22. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
23. A Phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
24. A Phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
25. A Phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias
26. Analysis of survival by tumor response
27. Logistic regression for binary response variables
28. Robust locally weighted regression and smoothing scatterplots
29. Results of decitabine therapy in accelerated and blastic phase of chronic mylogenous leukemia